What's News at Nucro-Technics

CHA and Nucro-Technics Announce New Market Investigation

by Constantine on April 5, 2012

Cambridge Healthtech Associates to deliver research on market opportunity for pre-clinical assay. Assay will evaluate potential toxicity in drug candidates

NEEDHAM, Massachusetts and SCARBOROUGH, Ontario – April 5, 2012 – Cambridge Healthtech Associates™ (CHA™) and Nucro-Technics, a full-service Contract Support Organization, today announced a new partnership focused on a market evaluation of a new biomarker tool set to predict safety adverse events. The goal is develop a novel pre-clinical, fee-for-service assay for use in the evaluation of the potential toxicity of new drug candidates.

“We see this project as an opportunity to explore a new and exciting program that will help our clients make informed decisions about bringing new drug candidates to market,” said Bedrich Videl, Special Projects, at Nucro-Technics, “We are continually striving to provide new products that meet the needs of the biopharmaceutical industry.”

CHA will conduct interviews with leaders in the pharmaceutical and biotech industries to gain an understanding of the current market landscape in drug safety biomarkers, assess the market needs and priorities on drug safety and biomarkers, and examine how the safety screening field is evolving.

“We are looking forward to this research project,” said Dr. Ernie Bush, Scientific Director, at CHA. “Helping clients like Nucro-Technics assess the market’s interest in drug safety biomarkers is essential to understanding the status of this technology, and the optimal ways of moving forward to gain benefit for the pharma industry and patient health.”

About Cambridge Healthtech Associates
Cambridge Healthtech Associates™ (CHA™) uses its unique collaborative model to improve the speed, economics and effectiveness of life science research and development, leveraging its consulting, technology evaluations and communities to help clients in the industry achieve their individual goals. Read more at www.chacorporate.com.

Cambridge Healthtech Associates also manages the Drug Safety Executive Council™ (DSEC™) a community of drug safety professionals focused on the development of better and safer medicines and can be found at www.drugsafetycouncil.org.

About Nucro-Technics
Nucro-Technics is a full-service Pharmaceutical Contract Support Organization that has completed projects for the ten largest pharmaceutical companies worldwide.  Nucro-Technics’ in-house services include: Pre-Clinical Toxicology; Genetic Toxicology; Bioanalytical Services; Chemistry/Microbiology Analysis & Method Development; and Quality Control/Quality Assurance/Regulatory Affairs consulting to the biotech, pharmaceutical and medical device industries. Read more at www.nucro-technics.com.

Contact:

Cambridge Healthtech Associates
Contact: Alison Serrano
Tel: + 1 (781) 972-5482
Email: aserrano@chacorporate.com

Nucro-Technics
Contact: Constantine Fanaras
Tel: +1 (416) 438-6727
Email: info@nucro-technics.com

Previous post:

Next post: